Alterity Therapeutics Limited ATHE
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -46.27%
- 1 year
- -54.41%
5D -0.54 (-24.11%)
- Market cap
- 31.60M
- Revenue (ttm)
- 4.02M
- EPS (ttm)
- -0.90
- Shares out
- 8.74M
- Forward P/E
- -27.22
- YTD return
- -46.27%
- 1-year return
- -54.41%
- 50-day average
- 1.48
- 200-day average
- 1.67
- Volume
- 36.19K
- Avg volume
- 89.25K
- Open
- 1.70
- Previous close
- 1.70
- Day's range
- 1.52 – 1.70
- 52-week range
- 1.52 – 5.89
- Beta
- 0.68
- Analysts
- Buy
- Price target
- 8.00 (+383.4%)
Key statistics
- Enterprise value
- 11.69B
- Price / sales
- 5.33
- Price / book
- 816.67
- Revenue growth
- 38.40%
- Free cash flow
- -5.36M
- Total cash
- 12.64M
- Total debt
- 159.04K
- Return on equity
- -104.47%
- Short % of float
- 0.02%
Fundamental scorecard
4 of 25 checks passed on ATHE’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Maxim Group | init | — | Buy |
| Mar 7, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Jun 5, 2023 | Ladenburg Thalmann | main | Buy | Buy |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- alteritytherapeutics.com
News
Your note
Sign in to keep a note on ATHE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.50% | 44,501 | 109.03K | Sep 29, 2024 |
| HB Wealth Management, LLC | 0.27% | 23,783 | 58.27K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.16% | 13,932 | 34.13K | Sep 29, 2024 |
| UBS Group AG | 0.14% | 12,685 | 31.08K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 11,488 | 28.14K | Sep 29, 2024 |
| Twin Lakes Capital Management, LLC | 0.07% | 5,925 | 14.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,155 | 2.83K | Oct 30, 2024 |
